References
- Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.
- Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655–664.
- Burton T, Le Nestour E, Neary M, et al. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19(3):262–267.
- Gatto F, Trifiro G, Lapi F, et al. Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine. 2018;61(3):533–541.
- Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439–446.
- Kamusheva M, Vandeva S, Mitov K, et al. New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria. Front Public Health. 2020;8:147.
- Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.
- Webb SM, Badia X, Surinach NL, et al. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol. 2006;155(2):269–277.
- Solomon E, Branisteanu D, Dumbrava A, et al. Executive functioning and quality of life in acromegaly. Psychol Res Behav Manag. 2019;12:39–44.
- Bolfi F, Neves AF, Boguszewski CL, et al. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59–71.
- Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101264.
- Corica G, Ceraudo M, Campana C, et al. Octreotide-resistant acromegaly: challenges and solutions. Ther Clin Risk Manag. 2020;16:379–391.
- Gurel MH, Han Y, Stevens AL, et al. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC Pharmacol Toxicol. 2017;18(1):22.
- Camara R, Venegas E, Garcia-Arnes JA, et al. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study. Pituitary. 2019;22(2):137–145.
- Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561.
- Chen CJ, Ironside N, Pomeraniec IJ, et al. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir (Wien). 2017;159(11):2193–2207.
- Hannon MJ, Barkan AL, Drake WM. The role of radiotherapy in acromegaly. Neuroendocrinology. 2016;103(1):42–49.
- Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156(1):65–74.
- Gatto F, Arvigo M, Ferone D. Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest. 2020. DOI:10.1007/s40618-020-01335-0
- Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014;52(3):R223–40.
- Gunther T, Tulipano G, Dournaud P, et al. International union of basic and clinical pharmacology. CV. somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70(4):763–835.
- Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–4473.
- Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799.
- Paragliola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary. 2017;20(1):109–115.
- Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884.
- Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161(2):331–338.
- Giustina A, Mazziotti G, Cannavo S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017;102(7):2454–2464.
- Muhammad A, Coopmans EC, Delhanty PJD, et al. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol. 2018;179(5):269–277.
- Luger A. Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment. Endocrine. 2016;54(1):1–2.
- Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary. 2017;20(1):121–128.
- Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–1335.
- Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–1177.
- van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–1759.
- Buchfelder M, van der Lely AJ, Biller BMK, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419–427.
- Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010;95(2):552–558.
- Lesen E, Granfeldt D, Houchard A, et al. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017;176(2):203–212..
- Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. 2004;27(11):1034–1039.
- Roset M, Merino-Montero S, Luque-Ramirez M, et al. Cost of clinical management of acromegaly in Spain. Clin Drug Investig. 2012;32(4):235–245.
- Elbaum M, Mizera L, Bolanowski M. The real costs of acromegaly: analysis of different therapies. Endokrynol Pol. 2019;70(1):74–85.
- Orlewska E, Stepien R, Orlewska K. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2019;19(1):15–25.
- Biermasz NR, Roelfsema F, Pereira AM, et al. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):223–234.
- Ibanez-Costa A, Lopez-Sanchez LM, Gahete MD, et al. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep. 2017;7:42002.
- Rocheville M, Lange DC, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288(5463):154–157.
- Crinetics: corporate presentation. 2019 Aug [cited 2020 May 25]. Available from: http://ir.crinetics.com/static-files/2ea9a59f-6b47-4e18-a428-579ca263bf54
- Trainer PJ, Newell-Price JDC, Ayuk J, et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. Eur J Endocrinol. 2018;179(2):97–108.
- Safety, tolerability, and efficacy of IONIS-GHR-LRx in patients with acromegaly being treated with long-acting somatostatin receptor ligands. [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03548415?term=IONIS-GHR-LRx&draw=2&rank=2
- Extension Study of IONIS-GHR-LRx administered to participants with acromegaly being treated with long-acting somatostatin receptor ligands. [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03967249?term=IONIS-GHR-LRx&draw=2&rank=1
- Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699–1708.
- Tachas G, Lofthouse S, Wraight CJ, et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol. 2006;189(1):147–154.
- Ionis Pharmaceuticals I. FORM 10-K 2017. [ cited 2020 May 25]. Available from: https://www.sec.gov/Archives/edgar/data/874015/000087401518000047/form10k.htm
- Culler MD. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Hormone Metab Res. 2011;43(12):854–857.
- Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005;153(1):135–141.
- Halem HA, Hochgeschwender U, Rih JK, et al. TBR-760, a dopamine-somatostatin compound, arrests growth of aggressive nonfunctioning pituitary adenomas in mice. Endocrinology. 2020;161(8). DOI:10.1210/endocr/bqaa101
- Kim J, Oh JH, Harlem H, et al. Therapeutic effect of a novel chimeric molecule targeting both somatostatin and dopamine receptors on growth hormone-secreting pituitary adenomas. Endocrinol Metab. 2020;35(1):177–187.
- Vazquez-Borrego MC, LL F, Galvez-Moreno MA, et al. A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells. Neuroendocrinology. 2020;110(1–2):70–82.
- Assessment of BIM23B065, given as repeated subcutaneous injection in subjects with acromegaly (DOPAACRO 002). [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03045302?term=BIM-23B065&draw=2&rank=1
- The effect of subcutaneous infusions of 3 doses of DG3173 on growth hormone levels in untreated acromegalics. [ cited 2020 May 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02217800
- Endocrine abstracts. 18th European congress of endocrinology 2016. Munich, Germany: bioscientifica; 2016. p. GP123.
- Biopharma S. Veldoreotide modified release: a novel somatostatin analogue. [ cited 2020 May 25]. Available from: https://www.strongbridgebio.com/products/veldoreotide/
- Betz S, Markison S, Kusnetzow A, et al. Suppression of growth hormone and insulin-like growth factor 1 in rats after oral administration of CRN00808, a small molecule, SST2 selective somatostatin biased agonist. 2018 [cited 2020 May 25]. Available from: https://www.abstractsonline.com/pp8/#!/4482/presentation/6931
- Madan A, Zhu Y, Markison S, et al. Final results from the first in man phase 1 clinical trial of CRN00808, an orally bioavailable sst2-selective, nonpeptide somatostatin biased agonist, for the treatment of acromegaly: safety, pharmacokinetics, pharmacodynamics, and midazolam drug interaction in healthy volunteers. J Endocr Soc. 2019 April–May;3(Supplement_1):SAT–429.
- An study to evaluate the safety and efficacy of paltusotine for the treatment of acromegaly (ACROBAT edge). [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03789656?term=acrobat&draw=2&rank=5
- A study to evaluate the safety and efficacy of paltusotine for the treatment of acromegaly (ACROBAT evolve). [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03792555
- A study to evaluate the long-term safety and efficacy of paltusotine for the treatment of acromegaly (ACROBAT advance). [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04261712s
- Maffezzoni F, Formenti AM, Mazziotti G, et al. Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother. 2016;17(12):1631–1642.
- Phase II study with ITF2984 in acromegalic patients (POC). [ cited 2020 May 27]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02111044
- Chieffo C, Cook D, Xiang Q, et al. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab. 2013;98(10):4047–4054.
- Tuvia S, Pelled D, Marom K, et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014;31(8):2010–2021.
- Chiasma ANNOUNCES FDA approval of MYCAPSSA® (Octreotide) Capsules, the first and only oral somatostatin analog. [ cited 2020 Aug 14]. Available from: https://www.globenewswire.com/news-release/2020/06/26/2054210/0/en/Chiasma-Announces-FDA-Approval-of-MYCAPSSA-Octreotide-Capsules-the-First-and-Only-Oral-Somatostatin-Analog.html
- Study to determine the maximum tolerated dose, safety and tolerability of a single dose of lanreotide prolonged release formulation (PRF) in subjects with acromegaly. [ cited 2020 May 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02396953
- Pavel M, Borson-Chazot F, Cailleux A, et al. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother Pharmacol. 2019;83(2):375–385.
- A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with acromegaly. [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04076462
- A trial to assess the long-term safety of octreotide subcutaneous depot in patients with acromegaly. [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04125836
- Gatto F, Campana C, Cocchiara F, et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. 2019;20(3):365-381..